LY-2183240
Covalent FAAH inhibitor, first presented as an anandamide transport blocker, poorly selective.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₁₇H₁₇N₅O
CAS 874902-19-9
- Family
- ECS pharmacological toolEnzyme inhibitor
- Molar mass
- 307.35 g/mol
Updated on
In plain terms
LY-2183240 was presented as a blocker of anandamide transport into the cell. A 2006 study showed that it acts mainly by destroying the enzyme that degrades anandamide, and several other enzymes along the way. It is a classic example of a tool whose target was misunderstood; no study in humans was found.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to LY-2183240: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of LY-2183240.
FAAHFAAH found in 7 regions of the body
- CortexpresentCortical pyramidal neurons1
- Basal gangliapresentStriatal neurons1
- HypothalamuspresentPresent in hypothalamic nuclei1
- CerebellumpresentPurkinje cells and cerebellar layers1
- BrainstempresentInferior olivary nuclei1
- Adipose tissuepresentExpressed in mature adipocytes2
- BonepresentPresent on osteoclasts3
Map sources
- Romero J et al. Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res Mol Brain Res, 2002 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)
Cited values
- FAAHInhibitorno measured value cited
Potent covalent inhibitor by carbamylation of the nucleophilic serine; no numerical value in the abstract (Alexander and Cravatt 2006)
- Captation cellulaire de l'anandamideInhibitorno measured value cited
Inhibition of the cellular uptake of anandamide (Ortar et al. 2008); it could be due mainly to FAAH inactivation (Alexander and Cravatt 2006); no value taken from the abstracts
Pharmacology
LY-2183240 illustrates the risk of inferring a mechanism from a tool whose target one thinks one knows. It had been introduced as an inhibitor of the putative anandamide transporter: it disrupted the cellular uptake of this endocannabinoid and promoted analgesia in vivo. Alexander and Cravatt showed in 2006 that it is a potent covalent FAAH inhibitor, which it inactivates by carbamylation of the active-site serine nucleophile; the blockade of uptake may therefore be due primarily to inactivation of FAAH, and their activity-based proteomic screen revealed other brain serine hydrolases that it inhibits, hence the warning about this chemotype. Ortar and colleagues (2008) confirm that it inhibits both cellular uptake and hydrolysis of anandamide; Maione and colleagues (2008) report that, in mice, its antinociceptive effect in the formalin test is antagonised by rimonabant and attribute part of the activity of this tetrazole class to uptake inhibition independent of FAAH. These results are preclinical; no study in humans was found.
Key sources.
- Alexander JP, Cravatt BF. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc, 2006 (new tab)PMID 16866524
- Ortar G et al. Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation. Eur J Med Chem, 2008 (new tab)PMID 17452063
- Maione S et al. Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. Br J Pharmacol, 2008 (new tab)PMID 18660824
- PubChem, LY-2183240, CID 11507802 (identifiers and properties) (new tab)
History
- Source
- An entirely synthetic compound with no natural occurrence. It is known as a pharmacological research reagent; no clinical trial or human use was found in the sources consulted.
Origin
Research tool
No biological pathway: LY-2183240 is a synthetic compound of the carbamoyl tetrazole class (heterocyclic ureas), unrelated to the plant cannabinoid pathway.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It is not listed in the schedules of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025, text reviewed). No marketing authorisation was found.
- France
Not classified: LY-2183240 is not on the ANSM consolidated list of narcotics (updated 16/02/2026) and this carbamoyl tetrazole falls within none of the generic families of that list. No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Enzyme inhibitor
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Alexander JP, Cravatt BF. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc, 2006 (new tab)PMID 16866524
- Ortar G et al. Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation. Eur J Med Chem, 2008 (new tab)PMID 17452063
- Maione S et al. Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. Br J Pharmacol, 2008 (new tab)PMID 18660824
- PubChem, LY-2183240, CID 11507802 (identifiers and properties) (new tab)
Identifiers
Names
- IUPAC name
- N,N-dimethyl-5-[(4-phenylphenyl)methyl]tetrazole-1-carboxamide
- Other names
- LY2183240 · LY 2183240
Identifiers
- Formula
- C₁₇H₁₇N₅O
- CAS
- 874902-19-9
- PubChem CID
- 11507802(new tab)
- InChIKey
- GZNIYOXWFCDBBJ-UHFFFAOYSA-N
- SMILES
- CN(C)
C(= O) N1C(= NN= N1) CC2= CC= C(C= C2) C3= CC= CC= C3
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.